San Diego, CA (PressExposure) October 13, 2013 -- Dr. Anne De Groot, Founder, CEO and Chief Scientific Officer of EpiVax will give a featured presentation discussing her recent article in the Journal of Clinical Immunology, "T-cell Dependent Immunogenicity of Protein Therapeutics: Preclinical Assessment and Mitigation" at the 2nd Annual Immunogenicity and Immunotoxicity Conference to be held on January 29-31, 2014 in San Diego, CA by GTC.
The article which includes Vibha Jawaa, Amgen; Leslie P. Counsens, EpiVax; Michel Awwad, Pfizer; Eric Wakshull, Genentech; and Harald Kropshofer, Roche as authors will focus on the Td contribution to immunogenicity, summarizing current approaches for the prediction and measurement of T cell-dependent immune responses to protein biologics, discussing the advantages and limitations of these technologies, and suggesting a practical approach for assessing and mitigating Td immunogenicity.
Dr. De Groot is internationally known for her research on protein therapeutics and vaccines. She discovered Tregitope, an immunodulator that has already changed the field of immunogenicity screening, and is a promising first-in-class therapeutic agent for autoimmune disease. Dr. De Groot's NIH-funded research focuses on Tregitopes and Immunogenicity, as well as immunoinformatics-driven immunotherapy and vaccine design; she has authored more than 170 peer-reviewed publications.
She is founder, CEO and chief scientific officer of EpiVax which develops and employs extensive comprehensive analytical capabilities in the field of computational immunology. Dr. De Groot directs EpiVax's business strategy, marketing, and scientific efforts. She is also a Director and professor at the Institute for Immunology and Informatics at the University of Rhode Island (iCubed). While serving as a leader in industry and academia, Dr. De Groot also practices internal medicine at a local clinic for patients affected by health disparities.
The Immunogenicity and Immunotoxicity Conference will provide guests with a better understanding of the ongoing research for tools to mitigate risks associated with the immunogenicity of therapeutic proteins. Guests will get an up-to-date understanding of the mechanisms and consequences of protein aggregation and insights on how to prosecute state-of-the-art assessment of the clinical immunogenicity of therapeutic proteins.
This conference is also part of the Novel Immunotherapeutics Summit 2014, which consists of this track and three other tracks:
I. 6th Immunotherapeutics and Immunomonitoring
II. Innate Immunity
III. 12th Cytokines and Inflammation
For more information, please visit http://www.gtcbio.com/igit